A deletion mutation in Slc12a6 is associated with neuromuscular disease in gaxp mice

Genomics

Volumn 91, Issue 5, 2008, Pages 407-414

  Jiao, Yan ^a,e   Jin, Xiudong ^a,e   Yan, Jian ^a,e   Zhang, Chi ^a,e   Jiao, Feng ^a,e   Li, Xinmin ^b,e   Roe, Bruce A ^c,e   Mount, David B ^d,e   Gu, Weikuan ^a,e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MUDANJIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Genome; Giant axonopathy; High throughput screening; Microarray; Mouse; Mutation

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; POTASSIUM CHLORIDE COTRANSPORTER;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DNA MICROARRAY; EXON; GENE; GENE DELETION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; MEDLINE; MOUSE; NEUROMUSCULAR DISEASE; NEUROPATHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC12A6 GENE; VALIDATION PROCESS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ATAXIA; AXONS; DNA MUTATIONAL ANALYSIS; EXONS; GENE DELETION; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SYMPORTERS;

MUS;

EID: 42049107729     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2007.12.010     Document Type: Article

References (31)

1. Hortnagel K., et al. Infantile neuroaxonal dystrophy and pantothenate-kinase-associated neurodegeneration: locus heterogeneity. Neurology 14 (2004) 922-924
2. Umemura A., Jaggi J.L., Dolinskas C.A., Stern M.B., and Baltuch G.H. Pallidal deep brain stimulation for longstanding severe generalized dystonia in Hallervorden-Spatz syndrome (case report). J. Neurosurg. 100 (2004) 706-709
3. Marotti J.D., Tobias S., Fratkin J.D., Powers J.M., and Rhodes C.H. Adult onset leukodystrophy with neuroaxonal spheroids and pigmented glia: report of a family, historical perspective, and review of the literature. Acta Neuropathol. (Berlin) 107 (2004) 481-488
4. Thomas M., Hayflick S.J., and Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov. Disord. 19 (2004) 36-42
5. Allen E., et al. Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. Nature 438 (2005) 224-228
6. Cullen V.C., et al. Gigaxonin is associated with the Golgi and dimerises via its BTB domain. Neuroreport 15 (2004) 873-876
7. Bomont P., et al. Identification of seven novel mutations in the GAN gene. Hum. Mutat. 21 (2003) 446
8. Bomont P., et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat. Genet. 26 (2000) 370-374
9. Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature 420 (2002) 520-562
10. Jiao Y., et al. Identification of a deletion causing spontaneous fracture by screening a candidate region of mouse chromosome 14. Mamm. Genome 16 (2005) 20-31
11. Jiao Y., et al. Carbonic anhydrase-related protein VIII deficiency causes a distinctive lifelong gait disorder in waddles mice. Genetics 171 (2005) 1239-1246
12. Meng H., Walker N., Su Y., and Qiao X. Stargazin mutation impairs cerebellar synaptogenesis, synaptic maturation and synaptic protein distribution. Brain Res. 1124 (2006) 197-207
13. Richardson C.A., and Leitch B. Cerebellar Golgi, Purkinje, and basket cells have reduced gamma-aminobutyric acid immunoreactivity in stargazer mutant mice. J. Comp. Neurol. 453 (2002) 85-99
14. Olson J.M., et al. NeuroD2 is necessary for development and survival of central nervous system neurons. Dev. Biol. 234 (2001) 174-187
15. Jones K.R., Farinas I., Backus C., and Reichardt L.F. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 76 (1994) 989-999
16. 2+ release and transmitter exocytosis at frog motor nerve terminals. Cell Calcium 38 (2005) 557-567
17. Nassenstein C., et al. The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. J. Exp. Med. 198 (2003) 455-467
18. Uyanik G., et al. Novel truncating and missense mutations of the KCC3 gene associated with Andermann syndrome. Neurology 66 (2006) 1044-1048
19. Meyer J., et al. Rare variants of the gene encoding the potassium chloride co-transporter 3 are associated with bipolar disorder. Int. J. Neuropsychopharmacol. 8 (2005) 495-504
20. Howard H.C., et al. The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum. Nat. Genet. 32 (2002) 384-392 [Erratum in Nat. Genet. 32 (2002) 681]
21. - cotransport: the SLC12 family. Pflugers Arch. 447 (2004) 580-593
22. Dupre N., et al. Hereditary motor and sensory neuropathy with agenesis of the corpus callosum. Ann. Neurol. 54 (2003) 9-18
23. Boettger T., et al. Loss of K-Cl co-transporter KCC3 causes deafness, neurodegeneration and reduced seizure threshold. EMBO J. 22 (2003) 5422-5434
24. - cotransporter. Am. J. Physiol., Renal Physiol. 289 (2005) F1246-F1261
25. Shen M.R., et al. The KCl cotransporter isoform KCC3 can play an important role in cell growth regulation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14714-14719
26. Klein T., Cooper T.G., and Yeung C.H. The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol. Reprod. 75 (2006) 853-858
27. Pearson M.M., Lu J., Mount D.B., and Delpire E. Localization of the K(+)-Cl(-) cotransporter, KCC3, in the central and peripheral nervous systems: expression in the choroid plexus, large neurons and white matter tracts. Neuroscience 103 (2001) 481-491
28. Byun N., and Delpire E. Axonal and periaxonal swelling precede peripheral neurodegeneration in KCC3 knockout mice. Neurobiol. Dis. 28 (2007) 39-51
29. Losson R., and Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 5134-5137
30. Frischmeyer P.A., and Dietz H.C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 8 (1999) 1893-1900
31. Holbrook J.A., Neu-Yilik G., Hentze M.W., and Kulozik A.E. Nonsense-mediated decay approaches the clinic. Nat. Genet. 36 (2004) 801-808